Cyrus R. Kumana

LKS Faculty Of Medicine
Sar, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

Acute Promyelocytic Leukemia Asian Consortium study of arsenic trioxide in newly diagnosed patients: impact and outcome.

Acute Promyelocytic Leukemia Asian Consortium study of arsenic trioxide in newly diagnosed patients: impact and outcome.

Journal: Blood advances
Published: October 04, 2024

Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021.

Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021.

Journal: BMC cancer
Published: October 20, 2022

Oral arsenic trioxide for treating acute promyelocytic leukaemia: Implications for its worldwide epidemiology and beyond.

Oral arsenic trioxide for treating acute promyelocytic leukaemia: Implications for its worldwide epidemiology and beyond.

Journal: Frontiers in oncology
Published: August 23, 2022

The Development and Clinical Applications of Oral Arsenic Trioxide for Acute Promyelocytic Leukaemia and Other Diseases.

The Development and Clinical Applications of Oral Arsenic Trioxide for Acute Promyelocytic Leukaemia and Other Diseases.

Journal: Pharmaceutics
Published: August 02, 2022

Characteristics and predictors of early hospital deaths in newly diagnosed APL: a 13-year population-wide study.

Characteristics and predictors of early hospital deaths in newly diagnosed APL: a 13-year population-wide study.

Journal: Blood advances
Published: March 19, 2021

Resurrection of Oral Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: A Historical Account From Bedside to Bench to Bedside.

Resurrection of Oral Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: A Historical Account From Bedside to Bench to Bedside.

Journal: Frontiers in oncology
Published: May 09, 2020

Oral arsenic trioxide, all-trans retinoic acid, and ascorbic acid maintenance after first complete remission in acute promyelocytic leukemia: Long-term results and unique prognostic indicators.

Oral arsenic trioxide, all-trans retinoic acid, and ascorbic acid maintenance after first complete remission in acute promyelocytic leukemia: Long-term results and unique prognostic indicators.

Journal: Cancer
Published: February 26, 2020

Oral arsenic trioxide incorporation into frontline treatment with all-trans retinoic acid and chemotherapy in newly diagnosed acute promyelocytic leukemia: A 5-year prospective study.

Oral arsenic trioxide incorporation into frontline treatment with all-trans retinoic acid and chemotherapy in newly diagnosed acute promyelocytic leukemia: A 5-year prospective study.

Journal: Cancer
Published: January 08, 2019

Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based reinduction and maintenance regimens: A 15-year prospective study.

Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based reinduction and maintenance regimens: A 15-year prospective study.

Journal: Cancer
Published: December 27, 2017

Network meta-analysis of cardiovascular outcomes in randomized controlled trials of new antidiabetic drugs.

Network meta-analysis of cardiovascular outcomes in randomized controlled trials of new antidiabetic drugs.

Journal: International journal of cardiology
Published: February 23, 2017

Minimising the costs of temperature monitoring in hospitals.

Minimising the costs of temperature monitoring in hospitals.

Journal: Postgraduate medical journal
Published: January 05, 2017

Absolute benefits of empagliflozin in type 2 diabetes: a game changer?

Absolute benefits of empagliflozin in type 2 diabetes: a game changer?

Journal: Postgraduate medical journal
Published: December 13, 2016
Showing 1-12 of 20

Last Updated: 09/26/2026